Brouwer et al. present preclinical evidence in support of a COVID-19 vaccine candidate, designed as a self-assembling two-component protein nanoparticle displaying multiple copies of the SARS-CoV-2 spike protein, which induces strong neutralizing antibody responses and protects from high-dose SARS-CoV-2 challenge.The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

antibodies, B cells, COVID-19, immunity, macaques, nanoparticles, protection, SARS-CoV-2, vaccine,
Department of Virology

Brouwer, P.J.M. (Philip J.M.), Brinkkemper, M. (Mitch), Maisonnasse, P. (Pauline), Dereuddre-Bosquet, N. (Nathalie), Grobben, M. (Marloes), Claireaux, M. (Mathieu), … Sanders, R.W. (Rogier W.). (2021). Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. doi:10.1016/j.cell.2021.01.035